The estimated Net Worth of Zachary William Stassen is at least $429 millier dollars as of 10 May 2022. Mr Stassen owns over 120,000 units of ViewRay stock worth over $16,409 and over the last 4 years he sold VRAY stock worth over $0. In addition, he makes $413,078 as Chief Financial Officer at ViewRay.
Mr has made over 3 trades of the ViewRay stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 120,000 units of VRAY stock worth $318,000 on 10 May 2022.
The largest trade he's ever made was buying 120,000 units of ViewRay stock on 10 May 2022 worth over $318,000. On average, Mr trades about 22,232 units every 32 days since 2020. As of 10 May 2022 he still owns at least 656,363 units of ViewRay stock.
You can see the complete history of Mr Stassen stock trades at the bottom of the page.
Zachary William Stassen is the Chief Financial Officer at ViewRay.
As the Chief Financial Officer of ViewRay, the total compensation of Mr Stassen at ViewRay is $413,078. There are 2 executives at ViewRay getting paid more, with Scott William Drake having the highest compensation of $1,406,115.
Mr Stassen is 42, he's been the Chief Financial Officer of ViewRay since . There are 4 older and no younger executives at ViewRay. The oldest executive at ViewRay Inc. is Robert Michael Fuchs, 54, who is the Chief HR Officer.
Zachary's mailing address filed with the SEC is C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE, OH, 44146.
Over the last 8 years, insiders at ViewRay have traded over $157,178,869 worth of ViewRay stock and bought 23,644,461 units worth $89,494,703 . The most active insiders traders include David P Bonita, International Ltd Fosun et Influence Ltd Strong. On average, ViewRay executives and independent directors trade stock every 35 days with the average trade being worth of $20,317. The most recent stock trade was executed by B Kristine Johnson on 21 July 2023, trading 30,702 units of VRAY stock currently worth $1,535.
mri-guided adaptive radiotherapy viewray®, inc. (nasdaq:vray), designs, manufactures, and markets the mridian® radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. mridian employs mri-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. mridian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. viewray believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients. at viewray, our vision is clear. we’re dedicated to giving doctors new and better ways to treat cancer with radiation therapy. we’re an entrepreneurial company with big ambitions, unlimited potential and a passion for improving
ViewRay executives and other stock owners filed with the SEC include: